The novel emerged SARS-CoV-2 has rapidly spread around the world causing acute
infection of the respiratory tract (COVID-19) that can result in severe disease and lethality …

The ubiquitously-expressed proteolytic enzyme furin is closely related to the pathogenesis of
SARS-CoV-2 and therefore represents a key target for antiviral therapy. Based on …

The spike protein (S) of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)
directs infection of the lungs and other tissues following its binding to the angiotensin …

Development of specific antiviral agents is an urgent unmet need for SARS-coronavirus 2
(SARS-CoV-2) infection. This study focuses on host proteases that proteolytically activate …

In cultured cells, SARS-CoV-2 infects cells via multiple pathways using different host
proteases. Recent studies have shown that the furin and TMPRSS2 (furin/TMPRSS2) …

SARS-CoV-2 enters cells via its spike glycoprotein which must be cleaved sequentially at
the S1/S2, then the S2'cleavage sites (CS) to mediate membrane fusion. SARS-CoV-2 has a …

SARS-CoV-2 is a respiratory pathogen and primarily infects the airway epithelium. As our
knowledge about innate immune factors of the respiratory tract against SARS-CoV-2 is …

The ongoing pandemic illustrates limited therapeutic options for controlling SARS-CoV-2
infections, calling a need for additional therapeutic targets. The viral spike S glycoprotein …

The pandemic coronavirus SARS-CoV-2 threatens public health worldwide. The viral spike
protein mediates SARS-CoV-2 entry into host cells and harbors a S1/S2 cleavage site …

The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) uses its spike (S)
protein to mediate viral entry into host cells. Cleavage of the S protein at the S1/S2 and/or …